Beta Bionics, Inc. (Nasdaq: BBNX) announced a proposed underwritten public offering of $125.0 million in shares of its common stock, according to a company statement.

The Irvine, California-based medical device company said it intends to grant underwriters a 30-day option to purchase up to an additional $18.75 million in shares. The company noted there is no assurance the offering will be completed or as to its final size or terms.

Beta Bionics said it plans to use net proceeds for general corporate purposes, which may include costs related to the commercialization of its Mint product, expansion of manufacturing facilities, research and development, clinical development, product enhancements, potential strategic opportunities, and working capital and operating expenses.

J.P. Morgan, Piper Sandler, Wells Fargo Securities, and Leerink Partners are serving as joint book-running managers for the offering.

The shares are being offered under a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on February 24, 2026, which became effective upon filing.